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Abstract: Multiple sclerosis (MS) affects the central nervous system leading to disability and is 
complicated by bone loss and fractures. Despite the acceptance of osteoporosis and fractures as 
two major public health problems, in people with MS the mechanisms have not been   investigated 
adequately. Physicians and patients usually focus on the major cause of disability and neglect 
the multiple risk factors for osteoporosis and fractures in this specific population. This review 
updates the epidemiology and physiopathological mechanisms in MS.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease affecting the brain and spinal 
cord1 leading to muscle weakness, coordination and balance problems, as well as sen-
sation disorders, visual and cognitive deficits, and gradual limitation of functioning.2 
Subjects with MS have multiple risk factors for osteoporosis, a disease characterized 
by low bone mass and destruction of the microarchitecture of bone tissue, resulting in 
increased bone fragility and susceptibility to fractures.3 In this pathological lesion of 
the brain and spinal cord there are differences according to the evolution or not of the 
lesion (ie, progressive MS vs relapsing remitting), residual mobility and functionality, 
the ability to walk and stand and drug treatment (ie, corticosteroid therapy, interferon 
therapy). In addition there are differences in the degree of spasticity experienced by 
MS subjects, a complication caused by alterations in the nerve impulses to the muscles 
resulting in spasms and stiffness. Disturbed coordination and balance in these subjects 
cause frequent falls.2 The element of fatigue and muscle weakness in disabilities such 
as MS needs to be taken into account because it reduces the mobility of these patients 
significantly.4 It is also obvious that patients with this disorder often face depression 
leading to difficulties in complying with the proposed treatments by physicians and 
limiting mobility.5
In relation to osteoporosis and fractures, the role of factors that do not change, 
such as race or gender of patients, has not been yet clarified, although a few studies in 
women have argued that bone mass in women with disabilities is more affected than 
men.6 Women with disabilities have a higher risk of osteoporosis than men because 
of the inevitable reduction in estrogen levels that occurs at menopause. Although 
there are several studies of bone mass in women with MS, higher rates of osteopenia 
and osteoporosis have been reported in women with spina bifida or spinal cord injury 





women with serious disabilities have low bone density is 
not surprising and is probably related to the lack of activity 
(reduced mobility, reduced loading on bone) and worsening 
of the disability.7
Epidemiology of osteopenia, 
osteoporosis, and fractures in MS
In a relatively young (mean age: 51.29 ± 8.7 years) male 
MS population, 80% of cases could be defined as osteopenia 
or osteoporosis.8 A study using North American Research 
Committee on Multiple Sclerosis (NARCOMS) Registry 
data reported that more than 25% of participants had low 
bone mass, while 15% of subjects had a history of frac-
ture after age 13 years. Among those reporting fractures 
46.2% reported multiple fractures, 35.2% wrist fracture, 
11.1% vertebral fracture, and 7.4% hip fracture. Moreover, 
15.1% of participants had one clinical risk factor for fracture 
(except age), 25.0% had two, and 57.7% had three or more. 
More than 50% of fracture subjects reported taking calcium 
supplements, 68.8% reported taking vitamin D supplements 
or a multivitamin with vitamin D, and 22.5% reported taking 
a bisphosphonate.9
Physiopathologic mechanisms
Physiopathology of bone loss in disabilities is multifactorial 
in acute and chronic phase. The main cause of osteoporosis 
is not well understood,10 although the problem was detected 
50 years ago.11,12 Furthermore, few studies have examined 
the relationship between osteoporosis and/or immobiliza-
tion with neurological disorders in which there is a gradual 
progressive or relapsing condition such as MS accompanied 
by bone loss. The disuse seems to play a role,13 but most 
believe that immobilization of these patients is a minor fac-
tor in the etiology of osteoporosis. The loss of mechanical 
stimuli in bone is a major challenge and has an effect on 
bone integrity. Reduced mobility has been implicated as 
an important factor in bone loss in patients suffering from 
MS and it seems to greatly influence bone mineral density 
(BMD) of the femur.14 Immobilization due to motor paraly-
sis from lesion of the central nervous system contributes to 
changes, which are: (a) the lack of the normal load applied 
to bone in the upright position and (b) the reduced number 
and intensity of muscle contractions. A severe form of MS 
can result in a wheelchair-bound patient having a clinical 
outcome equivalent to paraplegia, but another MS patient 
may have an appropriate walking gait pattern (ie, using ankle 
foot orthosis) or may also be bedridden. These situations 
result in a variable reduction of compressive forces on bone 
usually performed in an up right position. Moreover,   since 
ground reaction forces are reduced, muscle strength needed 
to produce movement is very low.15 Reduction of mechanical 
stress on bone inhibits osteoblast-mediated bone formation 
and accelerates osteoclast-mediated bone resorption, and 
leads to what has been called disuse osteoporosis.16 Grabois 
also reports that the primary factor for the activation of bone 
structure is weight bearing. Therefore, immobilization in 
general leads to osteoporosis from disuse, as evidenced by 
increased urinary calcium and reduced bone density.17 How-
ever, the high proportion of ambulatory patients with bone 
loss suggests additional nonmechanical factors.18
Spasticity is considered by many researchers to be a 
prophylactic factor for bone. It is well known that volun-
tary muscle contraction is effective in the prevention of 
osteoporosis.19,20 Muscle spasms and muscle tension in 
the presence of spasticity can put force on bones. This is 
likely to play a regulatory role in maintaining bone density. 
Patients without spasticity usually have more fractures. At the 
same time excessive spasticity may cause fractures through 
uncontrolled limb movements, ie, in a wheelchair. Therefore, 
spasticity probably has two effects on bone: a low grade of 
spasticity benefits, while a high spasticity grade could be 
detrimental.21,22 Studies in spinal cord-injured (SCI) subjects 
have reported controversial results for the effect of spastic-
ity on BMD, ie, either less reduction of BMD in the spastic 
SCI compared with flaccid SCI subjects, or spasticity may 
be protective against bone loss in SCI, but without any pre-
serving effect in the tibia.23 Only one MS study assessed the 
relationship between spasticity and bone strength, measured 
by quantitative ultrasound of cortical bone, using tibial speed 
of sound (SOS, m/second) at midpoint of the tibial shaft. 
Results showed preserved bone strength in MS patients and 
increased SOS related to spasticity in a subgroup of female 
patients.24
MS patients have a high incidence of vitamin D deficiency 
as defined by levels of 25-hydroxy vitamin D (25-OH D) 
,20 ng/mL.25 The reasons might be due to a combination of low 
dietary vitamin D intake and avoiding sun exposure, because MS 
symptoms may worsen after sun exposure (fatigue-related heat) 
leading these patients to avoid sun. There is a direct link between 
sunlight exposure and vitamin D3 production in the skin, which 
is biologically inactive but is converted by 25-hydroxylase 
(25-OHase) enzyme in the liver to 25-OH D, the circulating form 
of vitamin D. The low intake of vitamin D, which is supplied by 
food either in vitamin D2 (ergocalciferol, activated ergosterol), 
found in yeast, or vitamin D3 (cholecalciferol), found in fish, 
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On the other hand, we have no strong evidence to sup-
port supplementation because double-blind randomized 
placebo-controlled studies had insufficient power.27,28 Low 
testosterone alone in these populations does not explain 
bone loss and no clear effect of smoking or alcohol abuse 
on decreased bone mass could be established.8
In osteoporosis, molecular mechanisms leading to bone 
loss are inadequately explained. There is evidence of interac-
tion between bone and the immune system. T cell activity 
could stimulate bone loss under certain circumstances such 
as estrogen deficiency. Women with postmenopausal osteopo-
rosis have higher T cell activity than healthy postmenopausal 
subjects, which could also be the case in inflammatory or 
autoimmune disorders like MS; receptor activator of nuclear 
factor kappa B ligand (RANKL) stimulates osteoclas to 
genesis as do cytokines, such as tumor necrosis factor alpha, 
interleukin (IL)-1, or IL-11, all produced by T cell activa-
tion, leading to bone destruction. In contrast, osteoprotegerin 
(OPG) is an osteoclastogenesis inhibitory factor preventing 
the function of RANKL. A balanced system of RANKL/
OPG regulates bone metabolism. In MS the balance of this 
system is shifting from OPG to RANKL.29,30
Glucocorticoid (GC)-induced osteoporosis is the main type 
of secondary osteoporosis.31–36 The mechanism is that excess 
GCs cause a rapid and significant damage to bone quality. 
Now we know that GCs act directly on bone mainly through 
the stromal/osteoblastic lineage, and at high concentrations 
their differentiation, survival, and function is altered, causing 
a shift from osteoblastic to adipocytic differentiation of precur-
sors; inducing apoptosis of mature osteoblasts; and inhibiting 
synthesis and secretion of bone components.37,38 Finally, GCs 
promote osteoclasts and stimulate bone   resorption.39 The 
mechanisms of GCs action in bone have been studied exten-
sively. In patients receiving chronic oral GCs, bone loss occurs 
rapidly and is evident within 6 or even 3 months.18 A study 
investigating the effect of intravenous administration of GCs in 
MS patients found no clear effect on bone loss; on the contrary 
they reported an increase in BMD of the lumbar spine.40 Pro-
longed treatment with GCs results in increased risk of fractures, 
evident at 3 months, regardless of changes in BMD. High-dose, 
short-term intravenous treatment with GCs leads directly to 
reduction of bone formation and increased bone resorption, 
as indicated by markers of bone turnover.41,42 In the study by 
Zorzon et al, osteopenia, not osteoporosis was significantly 
more frequent in patients with MS than in controls, especially 
in women who received high-dose methylprednisolone pulses 
(HDMP) in relapse periods, highlighting the importance of 
regular monitoring of BMD in these patients. The authors 
concluded that disability and the subsequent immobilization 
that osteoporosis can result in is the more serious factor in 
this group and treatment with repeated HDMP pulses did not 
cause osteoporosis in MS subjects followed-up for almost 8 
years, unlike chronic corticosteroid therapy which induces 
osteoporosis and/or recovery of BMD is permitted without 
permanent skeletal damage.43
Besides GCs, in pharmaceutical management of MS, 
immunomodulatory, antiepileptic and antidepressant drugs 
are usually used. In Japanese women with rheumatoid arthri-
tis, methotrexate use was associated with a nonvertebral 
fracture risk, whereas methylenetetrahydrofolate reductase 
gene polymorphism status does not appear to be a clinically 
useful marker for predicting fracture risk.44 Moreover, 
researchers from St James’s Hospital in Ireland provided 
new insights into MS therapy with evaluation of bone mass 
in patients with MS on immunomodulatory therapy (IMT). 
BMD was measured by dual energy X-ray absorptiometry in 
37 patients with MS who received different IMTs: interferon 
beta-1a in 70%, interferonbeta-1b in 27%, and glatiramer 
in 3% was administrated combined with high-dose pulse 
corticosteroid therapy (intravenous methylprednisolone 
500 mg) in 81% ranging from 1 to 17 courses. Both mean 
BMD Z-score at spine of 0.53 (95% confidence intervals [CI]: 
0.15–0.92; P = 0.0084) and mean BMD Z-score at femur of 
0.72 (CI: 0.42–1.01; P , 0.0001) were significantly greater 
than zero, which suggested that IMT may have a favorable 
effect on bone in patients with MS even in the presence of 
pulse steroid therapy.36 The answer may lie in the molecular 
mechanisms regulating bone remodeling and underlying fac-
tors like induction of endogenous interferon beta (IFN-beta). 
The RANK-RANKL interaction induces IFN-beta and osteo-
clastogenesis via induction of the c-fos gene. The bond of 
IFN-beta to its biological receptor causes an inhibition of 
c-fos protein production and osteoclast proliferation and dif-
ferentiation.45 Moreover, with the use of enzyme-inducing 
antiepileptic drugs, bone loss is accelerated by the metabolism 
of vitamin D3, leading to decreased calcium absorption, 
secondary hyperparathyroidism, greater bone resorption, and 
a continuous negative feedback. It has been already shown 
that valproate stimulates osteoclast activity.46 The discovery 
of functional serotonin (5-hydroxytryptamine; 5-HT) trans-
porters (5-HTT) raised questions about the physiologic role 
of 5-HT in bone. 5-HT is linked to depression and 5-HTT 
is implicated in the physiopathology of this disease because 
5-HTT antagonists are the basic drugs of antidepressant 
  therapy. Studies support a relationship between selective sero-





in BMD, both in cross-sectional and   longitudinal analyses. 
Several large studies have demonstrated either similar or 
increased rates of hip fracture among SSRI users compared 
with tricyclic antidepressant users.47
Conclusion
All MS patients should be considered high risk for osteopo-
rosis and falls. Despite the fact that the design of studies is 
mostly cross-sectional, it is clear that MS induces bone loss. 
Prevention with calcium-rich foods, dietary supplements con-
taining vitamin D, and antiosteoporotic drugs is necessary for 
these patients. Particular attention should be paid to transfers 
and falls prevention in this population to prevent fractures, 
which occur easily and heal slowly.48 The ranking system of 
the World Health Organization created for postmenopausal 
osteoporosis focused mainly on healthy people. At the same 
time, despite the increased number of risk factors in people 
with MS there are no guidelines on BMD measurements. 
Future studies need to focus on this issue and also to find 
answers on neural control in bones.
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